Marshall syndrome – a challenge in medical practice

Cecilia Lazea, Rodica Manasia, Călin Lazăr*

Marshall syndrome (periodic fever, adenitis, pharyngitis, aphthae, PFAPA syndrome) is characterized by recurrent episodes of fever associated with aphthous stomatitis, cervical adenitis or pharyngitis. Although it is the most common cause of recurrent fever in children, the diagnosis is rarely established. The aim of this study was to describe a group of Romanian children with Marshall syndrome. In seven children with PFAPA, the following methods were used: patient history, clinical examination, and determination of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and tumor necrosis factor α (TNF-α). The treatment consisted in prednisone at a dose of 1 mg/kg. The age at onset was 2.2 years and at diagnosis 4.8 years. The mean interval between episodes was 3.1 weeks and the duration per febrile episode was 3.7 days. The patients presented with pharyngitis (100%), adenitis (100%) and aphthous lesions (57.1%). The mean ESR value was 31 mm/h, CRP 7.8 mg/dL and leukocytes 17700/mm³. TNF-α remained elevated between febrile episodes. Six patients treated with prednisone had favorable evolution. In conclusion, PFAPA should be suspected in children with periodic fever associated with pharyngitis, cervical adenitis and aphthous stomatitis.

Keywords: Marshall syndrome; fever

INTRODUCTION

Marshall syndrome (periodic fever, adenitis, pharyngitis, aphthae, PFAPA syndrome) consists of recurrent episodes of fever associated with aphthous stomatitis, pharyngitis and cervical adenitis. It was first described in 1987 by Marshall and it is characterized by episodes of fever lasting for 3-6 days with recurrence every 3-8 weeks, associated with at least one of the three main signs: aphthous stomatitis, cervical adenitis and pharyngitis (1, 2). The febrile episodes can spike to 39-40ºC, with little or no response to common antipyretics. Other symptoms may be present during fever attacks, such as headache, joint pain, myalgia, nausea, vomiting and abdominal pain. Onset of the disease is before the age of 5 years and usually lasts up to the age of 10-11 years, but there are some cases diagnosed in adults (3, 4). Patients are asymptomatic between episodes and have normal growth and development (2, 3, 5). The etiology is still unknown, but studies on cytokine concentrations showed a significant increase in serum proinflammatory cytokine levels (interleukin (IL)-1β, IL-6 and tumor necrosis factor α (TNF-α)) during and between febrile episodes and reduction in anti-inflammatory cytokine levels (IL-4 and IL-10) in these patients (6-8).

There are no diagnostic tests for PFAPA syndrome. The diagnosis is based on clinical criteria and exclusion of other possible causes of recurrent fever in children. During febrile attacks, patients present elevation of white blood cells, with preponderance of neutrophils and of acute phase reactants. Procalcitonin has normal values during flares and this finding can exclude bacterial infection (9, 10). Between attacks, all inflammatory parameters are normal.

The most effective methods of treatment are corticosteroids and tonsillectomy.

Although it is the most common cause of recurrent fever in children, the diagnosis is rarely established.

The aim of the present study was to assess clinical and laboratory characteristics of seven children with PFAPA syndrome in order to review the criteria for its accurate diagnosis and to avoid unnecessary use of antibiotics.

*“Iuliu Hațieganu” University of Medicine and Pharmacy, 1st Department of Pediatrics, Emergency Pediatric Hospital, Cluj-Napoca, Romania

Correspondence to:
Cecilia Lazea, Emergency Pediatric Hospital, 1st Department of Pediatrics, 68, Motilor street, 400370 Cluj-Napoca, Romania,
e-mail: cecilialazea@umfcluj.ro

Primljeno/Received: 3. 9. 2014., Prihvaćeno/Accepted: 10. 11. 2014.
PATIENTS AND METHODS

Seven children (5 girls and 2 boys) with recurrent episodes of fever were evaluated for PFAPA syndrome. The diagnosis of PFAPA syndrome was established according to the criteria proposed by Thomas: (a) regularly recurrent fever; (b) onset at an early age; (c) absence of upper respiratory tract infection; and (d) at least one of the following clinical signs: pharyngitis, aphthous stomatitis or cervical adenitis. Additional criteria included completely asymptomatic intervals between febrile episodes, normal growth and development, and exclusion of cyclic neutropenia.

An informed consent was obtained from participants or their guardians prior to enrolment in the study and the principles of human research ethics were fully respected. We recorded medical data for each patient. These included demographic data and medical history of patients and their families; characteristics of febrile episodes; laboratory evaluation; and treatment used. For laboratory evaluation, we followed peripheral leukocyte count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), procalcitonin, immunoglobulin and tumor necrosis factor alpha (TNF-α) concentration during and 10 days after fever attacks. The treatment consisted of prednisone at a dose of 1 mg/kg.

RESULTS

The main reason for hospitalization of children was recurrent pharyngitis for which they underwent repeated antibiotic treatments. The family medical history of the patients revealed PFAPA syndrome in one patient and autoimmune disease in another patient.

Clinical characteristics of PFAPA episodes in our patients are shown in Table 1. The mean age at onset of the disease was 2.2±0.9 years; the mean age at diagnosis was 4.8±3.2 years; the mean duration of episodes was 3.7±0.7 days; the mean maximal temperature was 39.6±0.5 ºC; and the mean frequency of febrile episodes was 3.1±0.8 weeks.

Laboratory evaluation of the patients during and between PFAPA episodes is shown in Table 2. Quantitative immunoglobulin levels were normal in all children.

Six children underwent treatment with prednisone at a dose of 1 mg/kg and the frequency of episodes decreased to once in 2 or 3 months. In one patient who failed to respond to prednisone administration, tonsillectomy resulted in complete remission.

DISCUSSION

We report on a group of Romanian PFAPA patients and their clinical and laboratory characteristics. Although PFAPA syndrome is nowadays considered as the most common of various auto-inflammatory fever disorders and its clinical manifestations are well known, the diagnosis is rarely established by pediatricians or primary care physicians and our patients underwent repeated unnecessary antibiotic treatments because the disease is commonly confounded with bacterial pharyngitis.

All seven patients were evaluated for recurrent acute pharyngitis and two of them had a family history of autoimmune disease and PFAPA syndrome, similar to the prevalence reported previously (11).

There are studies which suggest that PFAPA syndrome could have a genetic origin. This hypothesis is supported by the presence of MEFV (Mediterranean fever) gene mutations in a few patients with PFAPA syndrome (12). Other explanations involve the presence of this disease in siblings and clinical similarity with other periodic fever syndromes of genetic origin (12, 13). The disease occurs because of an abnormal immune response to infectious agents (virus) at the level of lymphoid organs (tonsils), which induce cell activation of innate immunity (12-14).
We compared our group with the groups published in the literature (Table 3). The clinical presentation of our group showed a long period (2 years) between the clinical onset and diagnosis because general practitioners who are the first to see the patients are not well acquainted with this entity. The mean duration of febrile episodes, the frequency of episodes and the mean maximal temperature were similar to those described previously (11, 15, 16). The patients were given more than 6 unnecessary treatments with antibiotics in 12 months preceding their presentation to our service. Clinical presentation included pharyngitis in all children (57.1% of them with exudative pharyngitis), cervical adenopathy in all children, and aphthous stomatitis in 57.1% of children. During relapses, the patients presented elevation of white blood cells and acute phase reactants (ESR, CRP), which normalized between attacks. Procalcitonin did not increase during fever attacks. This indicates that an association of high serum CRP with elevated leukocyte count and undetectable levels of procalcitonin could be used to distinguish PFAPA attack from bacterial infection (10). The levels of the proinflammatory cytokine TNF-α were elevated during and between PFAPA episodes, an observation that suggests dysregulation of the immune response in PFAPA syndrome, with continuous proinflammatory cytokine activation (7, 17).

In six children, corticosteroid administration (prednisone 1 mg/kg) resulted in rapid resolution of fever, but did not prevent subsequent episodes of fever and did not change the course of the disease. A large number of studies report that febrile attacks became less frequent after the treatment with corticosteroids (7, 18, 19). Other studies report on beneficial effects of cimetidine, colchicine or thalidomide, but a small number of patients were treated (7, 18-21). The role of tonsillectomy in PFAPA syndrome is controversial. The arguments for tonsillectomy are preventing recurrence of episodes, increasing the intervals between relapses, reducing the severity of the clinical manifestations, and inducing complete remission in 56%-100% of cases. The arguments against tonsillectomy are spontaneous resolution of PFAPA syndrome, possible persistent symptoms, and possible relapses after a period of remission. Therefore, tonsillectomy should be considered in case of intolerance or failure of the standard medical treatment (18-25).

**CONCLUSION**

Marshall syndrome should be suspected in children with periodic fever associated with pharyngitis, cervical adenitis and aphthous stomatitis. Although it is the most common cause of recurrent fever in children, it is commonly attributed to respiratory infection and the diagnosis is established long after the onset.

**TABLE 3. Clinical presentation of our group of children with PFAPA episodes and results of other studies**

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of patients</th>
<th>Age at onset (yrs)</th>
<th>Age at diagnosis (yrs)</th>
<th>Fever Recurrent</th>
<th>Duration (days)</th>
<th>Periodicity (weeks)</th>
<th>Maximal temperature (ºC)</th>
<th>Pharyngitis</th>
<th>Cervical adenitis</th>
<th>Aphthous stomatitis</th>
<th>Abdominal pain</th>
<th>Nausea, vomiting</th>
<th>Diarrhea</th>
<th>Arthralgia, myalgia</th>
<th>Headache</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas 1999</td>
<td>66</td>
<td>1.9</td>
<td>-</td>
<td>100%</td>
<td>-</td>
<td>-</td>
<td>40.1</td>
<td>65%</td>
<td>77%</td>
<td>67%</td>
<td>45%</td>
<td>-</td>
<td>30%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tasher 2006</td>
<td>54</td>
<td>1.5</td>
<td>-</td>
<td>100%</td>
<td>4.5</td>
<td>2.2</td>
<td>-</td>
<td>96%</td>
<td>61%</td>
<td>68%</td>
<td>65%</td>
<td>35%</td>
<td>13%</td>
<td>22%</td>
<td>46%</td>
</tr>
<tr>
<td>Padhe 2008</td>
<td>320</td>
<td>-</td>
<td>-</td>
<td>100%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100%</td>
<td>100%</td>
<td>83.8%</td>
<td>18%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gattorno 2009</td>
<td>130</td>
<td>3.1</td>
<td>-</td>
<td>100%</td>
<td>4.1</td>
<td>3.1</td>
<td>40.1</td>
<td>83.8%</td>
<td>100%</td>
<td>58.5%</td>
<td>53.1%</td>
<td>30.8%</td>
<td>29.2%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Feder 2009</td>
<td>105</td>
<td>1.15</td>
<td>-</td>
<td>100%</td>
<td>4.1</td>
<td>3.1</td>
<td>-</td>
<td>85%</td>
<td>62%</td>
<td>38%</td>
<td>41%</td>
<td>27%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>De Cunto 2010</td>
<td>12</td>
<td>3</td>
<td>-</td>
<td>100%</td>
<td>4</td>
<td>3</td>
<td>-</td>
<td>100%</td>
<td>83%</td>
<td>67%</td>
<td>42%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Yazgan 2012</td>
<td>12</td>
<td>3.7</td>
<td>-</td>
<td>100%</td>
<td>3</td>
<td>3</td>
<td>40</td>
<td>100%</td>
<td>78%</td>
<td>65%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Present study</td>
<td>7</td>
<td>4.8</td>
<td>-</td>
<td>100%</td>
<td>3.7</td>
<td>3.1</td>
<td>-</td>
<td>39.6</td>
<td>100%</td>
<td>57.1%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**NOVČANA POTPORA/FUNDING**

Nema/None

**ETIČKO ODOBRENJE/ETHICAL APPROVAL**

Nije potrebno/None

**DOPRINOSI AUTORA/DECLARATION OF AUTHORSHIP**

Lazea C. – study design, data analysis and interpretation, writing/umijanje studije, analiza rezultata i interpretacija, pisanje rada
Manasia R. – literature search, data interpretation, revising and final approval of the article/pretraživanje literature, interpretacija podataka, revizija i završno odobrenje rada
Lazar C. – data analysis, literature search, revising of the article/alaiza po datako, pretraživanje literature, revizija rada

SUOKIB INTERESA/CONFLICT OF INTEREST

Autori su popunili the Unified Competing Interest form na www.icmje.org/coi_disclosure.pdf (dostupno na zahtjev) obrazi razijaju: nemaju potporu niti jedne organizacije za objavljeni rad; nemaju financijsku potporu niti jedne organizacije koja bi mogla imati interes za objavu ovog rada u posljednje 3 godine; nemaju drugih veza ili aktivnosti koje bi mogle utjecati na objavljjeni rad. All authors have completed the Unified Competing Interest form on request from the corresponding author and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

REFERENCES

SAŽETAK

Marshalllov sindrom – izazov u kliničkoj praksi
C. Lazea, R. Manasia, C. Lazăr

Marshalllov sindrom (periodična groznica, adenitis, faringitis, afte, sindrom PFAPA) obilježen je opetovanim epizodama groznice udružene s aftoznim stomatitismom, cervikalnim adenitismom ili faringitismom. Iako je to najčešći uzrok opetovane groznice u djece, ova se dijagnoza rijetko postavlja. Cilj ovoga ispitivanja bio je opisati skupinu rumunjske djece s Marshallovim sindromom. U sedmoro djece s PFAPA primijenjene su sljedeće metode: anamneza, klinički pregled te određivanje sedimentacije eritrocita (SE), C-reaktivnog proteina (CRP) i faktora tumorske nekroze alfa (TNF-α). Liječenje je provedeno prednisonom u dozi od 1 mg/kg. Dob pri nastupu PFAPA bila je 2,2 godine, a pri dijagnozi 4,8 godina. Srednja vrijednost intervala među epizodama PFAPA bila je 3,1 tjedna, a trajanja pojedine febrilne epizode 3,7 dana. Bolesnici su imali faringitis (100%), adenitis (100%) i aftozne promjene (57,1%). Srednja vrijednost SE bila je 31 mm/h, CRP 7,8 mg/dL i leukocita 17700/mm³. TNF-α je ostao povišen između febrilnih epizoda. Povoljan ishod zabilježen je u šestoro bolesnika liječenih prednisonom. U zaključku, na PFAPA treba posumnjati u djece s periodičnim groznicama udruženim s faringitisom, cervikalnim adenitisom i aftoznim stomatitismom.

Ključne riječi: Marshalllov sindrom; groznica